Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Treatment and outcome in advanced invasive lobular breast cancer in the prospective German research platform OPAL

M. Thill, M.-O. Zahn, A. Welt, E. Stickeler, A. Nusch, T. Fietz, J. Rauh, N. Wetzel, L. Kruggel, M. Jänicke, N. Marschner, N. Harbeck, A. Wöckel, T. Decker and OPAL study group 2021

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal:
OPAL
2021
Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.

Link, H.,, Illerhaus, G., Martens, U. M., Salar, A., Depenbusch, R., Köhler, A., Engelhardt, M., Mahlmann, S., Zaiss, M., Lammerich, A., Bias P., Buchner, A.

Article

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: / Journal: Supportive Care in Cancer
AVOID
2020
Rare patients in routine care: Treatment and outcome in advanced invasive lobular breast cancer in the prospective German research platform OPAL

Thill M., Zahn M.-O., Welt A., Stickeler E., Nusch A., Fietz T., Rauh J., Wetzel N., Kruggel L., Jänicke M., Marschner N., Harbeck N., Wöckel A., Decker T., OPAL Registergruppe

Abstract

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
OPAL
2020
Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria

Bartsch R., Lüftner D., Balic M., Rinnerthaler G., Jackisch C., Müller V., Schmidt M., Harbeck N.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: St. Gallen IBCC / Journal:
ELEANOR
2021
Extendierte Adjuvanz mit Neratinib bei Patientinnen mit HER2+ frühem Mammakarzinom: eine multizentrische, prospektive, nicht-interventionelle Studie (NIS) in Deutschland und Österreich

Bartsch R., Lüftner D., Balic M., Rinnerthaler G., Jackisch C., Müller V., Schmidt M., Harbeck N.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal:
ELEANOR
2021
First line therapy with Lenalidomide and Dexamethasone in transplant-ineligible patients with multiple myeloma: Final results of the observational study FIRST-NIS.

Nückel H., Behlendorf T., Schulz H., Schulze M., Söling U., Bürkle D., Koenigsmann M., Medinger T., Dechow T., Schardt C., Vannier C., Niemeier B., Schmidt B., Rauh J., Potthoff K.

Download

Indikation: Multiple Myeloma, Multiples Myelom / Veranstaltung: EHA / Journal:
FIRST-NIS
2021
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)

Zeuschner P., Hölters S., Stöckle M., Seliger B., Mueller A., Bachmann H. S., Grünwald V., Christoph D.C., Stenzl A., Grimm M.-O., Brüning F., Goebell P. J., Augustin M., Roos F., Harde J., Benz-Rüd I., Staehler M., Junker K.

Abstract

pdf-Version

Indikation: Nierenzellkarzinom, Renal Cell Carcinoma / Veranstaltung: - / Journal: Cancers
MARC-2
2021
Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.

Staehler, M., Stöckle, M., Christoph, D. C., Stenzl, A., Potthoff, K., Grimm, M.-O., Klein, D., Harde, J., Brüning, F., Goebell, P. J., Augustin, M., Roos, F., Benz-Rüd, I., Marschner, N., Grünwald, V., 2020

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: / Journal: International Journal of Cancer
MARC-2
2021
Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients

Metz, M., Semsek, D., Rogmans, G., Hutzschenreuter, U., Fietz, T., Harde, J., Zacharias, S., Hielscher, C., Lorenz, A., Zahn, M.-O., Guth, D., Liebers, S., Berghorn, M., Grebhardt, S., Matillon, C. D., Egerer, G., Potthoff, K., 2021.

Abstract

pdf

Indikation: Breast Cancer, Mammakarzinom, Non-Hodgkin-Lymphom, Non-Hodgkin-Lymphoma / Veranstaltung: / Journal: Supportive Care in Cancer
CONVENIENCE
2021
An epidemiological, prospective cohort study for patients with HR+/HER2- advanced breast cancer treated 1st-line with an endocrine-based palbociclib combination therapy in real world in Germany and Austria

Lux, M. P., Resch, T., Fuxius, S., Gabrysiak, T., Amann, E., Buncke, J., Frank, M., Runkel, E. D., Thill, M., 2021.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal:
PERFORM
2021